Audit Report Correction: Qualified Opinion, Adverse Internal Control, Fraud Disclosure
- Audit opinion downgraded from unqualified to qualified due to scope limitation
- Internal accounting control system opinion changed to adverse
- Embezzlement/breach of trust disclosed in audit report
- Current financials: Total assets 114,973M KRW, liabilities 75,171M KRW, equity 39,802M KRW (capital erosion ratio -52.5%)
- Revenue 88,594M KRW, operating profit 596M KRW, net loss 2,074M KRW (continued net loss vs prior year)
- Capital stock 26,101M KRW vs equity 39,802M KRW (no capital impairment but debt ratio 188.8%)
- Audit report receipt date: 2026-04-30 (overdue)
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: [Correction of Description] Audit Report Submission
- Company: Dongsung Pharmaceutical (002210)
- Submission: Dongsung Pharmaceutical Co., Ltd.
- Receipt: 04-30-2026
- Under KRX KOSPI Market Division